Director Epstein’s 10b5‑1 Sale of 250 TEMPUS AI Shares Signals Strategic Portfolio Shift, Not Panic.
Investor insight: TEMPUS AI insider sales show strategic portfolio shifts, not distress—focus on precision‑medicine launches and market rebound potential.
3 minutes to read